Overview

Assessment of Rituximab Therapeutic Response Versus Conventional Treatment

Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
Prospective interventional comparative study to compare the efficacy of Rituximab versus Conventional treatment in Refractory Nephrotic Syndrome including patients on triple immunosuppression protocols.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ain Shams University
Treatments:
BB 1101
Cyclophosphamide
Cyclosporine
Cyclosporins
Dexamethasone
Dexamethasone acetate
Rituximab
Tacrolimus